miRNA in Chronic Kidney Diseases

The Role of miRNAs in the Regulation of Oxidative Stress and Microvascular Reactivity in Chronic Kidney Disease

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06316284

Enrollment

Registered

2024-03-18

Start date

2024-04-01

Completion date

2026-12-31

Last updated

2024-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Diseases

Keywords

chronic kidney diseases, miRNA, oxidative stress, hypertension

Brief summary

Oxidative stress and endoplasmic reticulum (ER) stress play a key role in tubular damage in both acute kidney injury and chronic kidney disease (CKD). Oxidative stress in the kidneys promotes renal vascular remodeling and increases preglomerular resistance. These are key elements in hypertension, acute and chronic kidney injury, as well as diabetic nephropathy. Chronic renal hypoxia is highlighted as the final common pathway to end-stage renal disease (ESRD). MicroRNA molecules (miRNA) also play an important role in these processes. MicroRNAs (miRNAs) are regulators of gene expression and play a role in the progression of renal ischemia-reperfusion injury. Although the pathophysiological contribution of microRNAs (miRNAs) to kidney damage has also been highlighted, the effect of miRNAs on kidney damage under conditions of oxidative and ER stress remains understudied.

Interventions

None listed

Study design

Observational model

CASE_CROSSOVER

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to 69 Years

Healthy volunteers

Yes

Inclusion criteria

* healthy normotensive adults (eGFR CKD-EPI \>90 mL/min/1.73 m2, BP \<140/90 mmHg) * hypertensive adults (eGFR CKD-EPI \>90 mL/min/1.73 m2, BP \>140/90 mmHg) * patients with chronic kidney disease stage 3-5 (eGFR CKD-EPI\< 60 mL/min/1.73 m2)

Exclusion criteria

* cardiovascular diseases, but hypertension * diabetes * cerebrovascular diseases * peripheral artery disease

Design outcomes

Primary

Measure	Time frame	Description
Systemic microvascular function	Day 1	Skin microvascular reactivity assessed by Laser Doppler flowmetry (post-occlusive reactive hyperemia, iontophoresis of acetylcholine and sodium nitroprusside) - measured in perfusion units (PU)
Serum level of antixidant enzymesprotein concentration of SOD, CAT and glutathione-peroxidase	Day 1	Serum protein concentration of superoxide disimutase (SOD), catalase (CAT) and glutathione-peroxidase (GPx).
Detecton of miRNA of interest	Day 1	The database for miRNA will be searched, and the miRNA of interest will be selected, determined and detected.

Secondary

Measure	Time frame	Description
Body fluid compartments	at one time point	Total body water (L), extracellular water (L), intracellular water (L) and plasma fluid volume (L) will be assessed using non-invasive bioimpedance analysis (BIA).

Countries

Croatia

Contacts

Primary ContactInes Drenjančević, MD, PhD

ines.drenjancevic@mefos.hr+38531512800

Outcome results